PR
-
Handok Obtains Domestic Approval for New Drug Pivlaz to Prevent Cerebral Vasospasm in Patients with Subarachnoid He..
Handok announced on December 7, 2023, that Pivlaz, a new drug for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage, has been approved by the Korean Ministry of Food and Drug Safety (MFDS). The marketing authorization for Pivlaz is held by Idorsia Pharmaceuticals Korea (IPK), with w..
2023.12.07 -
Handok Wins Health and Welfare Minister’s Innovative Pharmaceutical Company Award
On November 27, Handok received the Innovative Pharmaceutical Company Award from the Korean Ministry of Health and Welfare (MOHW). The MOHW annually recognizes innovative pharmaceutical companies that have contributed to the improvement of public health and advancement of the pharmaceutical industry by developing and di..
2023.12.01 -
Handok Receives IND for Global Phase 2/3 Study of HDB001A for Biliary Tract Cancer
On November 8, Handok announced that the Korean Ministry of Food and Drug Safety has approved the global Phase 2/3 Investigational New Drug (IND) Application for HDB001A in biliary tract cancer. The approval provides Handok with the opportunity to obtain additional data for HDB001A among Koreans. The Korean trial of HDB..
2023.11.10